A Phase 1, Open-Label, Parallel Group, Single Dose Study to Evaluate the Pharmacokinetics, Safety and Tolerability of EDP 305 in Subjects With Varying Degrees of Hepatic Function
Latest Information Update: 21 Sep 2022
At a glance
- Drugs EDP 305 (Primary)
- Indications Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis; Primary biliary cirrhosis
- Focus Pharmacokinetics
- Sponsors Enanta Pharmaceuticals
- 02 Nov 2017 Status changed from recruiting to completed.
- 04 Jul 2017 New trial record